Faron Pharmaceuticals Oy (OHEL:FARON) Long-Term Debt : €8.71 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Faron Pharmaceuticals Oy Long-Term Debt?

Faron Pharmaceuticals Oy's Long-Term Debt for the quarter that ended in Jun. 2024 was €8.71 Mil.

Faron Pharmaceuticals Oy's quarterly Long-Term Debt declined from Jun. 2023 (€10.89 Mil) to Dec. 2023 (€9.42 Mil) and declined from Dec. 2023 (€9.42 Mil) to Jun. 2024 (€8.71 Mil).

Faron Pharmaceuticals Oy's annual Long-Term Debt increased from Dec. 2021 (€2.92 Mil) to Dec. 2022 (€11.10 Mil) but then declined from Dec. 2022 (€11.10 Mil) to Dec. 2023 (€9.42 Mil).

Faron Pharmaceuticals Oy Long-Term Debt Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Long-Term Debt Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

2.26

2.73

2.92

11.10

9.42

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial															12.25	11.10	10.89	9.42	8.71

Faron Pharmaceuticals Oy (OHEL:FARON) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Faron Pharmaceuticals Oy Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (OHEL:FARON) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

FARN:UK 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.

Faron Pharmaceuticals Oy Headlines

No Headlines